tiprankstipranks
Analyst Profile
Followed by 389 other investors
.
Joseph Schwartz

Joseph Schwartz

SVB Securities
Wall Street Analyst
Ranked #7,621 out of 8,047 Analysts on TipRanks (#20,287 out of 21,521 overall experts)

Success Rate

45%
169 out of 372 Profitable Transactions

Average Return

-4.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Joseph Schwartz's ratings since 2009 and opened each position for the duration of 1 Year:
45.43% of your transactions would have been profitable with an average return of -4.7%

Stock Rating Distribution

884Ratings
86.54% Buy
12.56% Hold
0.90% Sell
Distribution of Joseph Schwartz's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
ChemoCentryx Inc
(CCXI)
Rating Type:Buy
Dates:Feb 14, 2019 - Feb 14, 2020
Gain:341.90%
The most profitable rating made by Joseph Schwartz

Joseph Schwartz's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
MAPP
Map Pharmaceuticals
Jun 15, 2009
Buy
Upgraded
0.00%
1
HGSI
Human Genome Sciences
Nov 02, 2009
Buy
Reiterated
0.00%
2
SVNTQ
Savient Pharmaceuticals
May 05, 2011
Sell
Downgraded
0.00%
2
OMTH
Omthera
May 30, 2013
Hold
Downgraded
0.00%
2
VPHM
Viropharma
Aug 02, 2013
Hold
Downgraded
0.00%
2
~RNA
Prosensa Holding
Sep 20, 2013
Buy
Reiterated
0.00%
2
Amarin
Oct 30, 2013
Hold
Downgraded
0.00%
6
NPSP
NPS Pharma
May 09, 2014
Buy
Initiated
0.00%
7
Cytokinetics
May 19, 2014
Buy
Initiated
$8.00
(-84.10% Downside)
0.00%
3
GEVA
Synageva
Jul 02, 2014
Hold
Reiterated
0.00%
4
List of latest recommendations made by Joseph Schwartz. Click to expand and see Joseph Schwartz's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More